CoChat

Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR

Open access
Lu, Hengyu, Liu, Chen, Huynh, Hung, Le, Thi Bich Uyen, LaMarche, Matthew J., Mohseni, Morvarid, Engelman, Jeffrey A., Hammerman, Peter S., Caponigro, Giordano, Hao, Huai-Xiang · 2020 · Oncotarget
Cited by 43

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

// Hengyu Lu 1 , Chen Liu 1 , Hung Huynh 2 , Thi Bich Uyen Le 2 , Matthew J. LaMarche 3 , Morvarid Mohseni 1 , Jeffrey A. Engelman 1 , Peter S. Hammerman 1 , Giordano Caponigro 1 and Huai-Xiang Hao 1 1 Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, Massachusetts, USA 2 Laboratory of Molecular Endocrinology, Division of Molecular and Cellular Research, National Cancer Centre, Singapore 3 Novartis Institutes for Biomedical Research, Global Discovery Chemistry, Cambridge, Massachusetts, USA Correspondence to: Huai-Xiang Hao, email: huaixiang.hao@novartis.com Keywords: SHP2; FGFR; resistance; feedback activation Received: October 17, 2019 Accepted: December 29, 2019 Published: January 21, 2020 ABSTRACT SHP2 mediates RAS activation downstream of multiple receptor tyrosine kinases (RTKs) and cancer cell lines dependent on RTKs are in general dependent on SHP2. Profiling of the allosteric SHP2 inhibitor SHP099 across cancer cell lines harboring various RTK dependencies reveals that FGFR-dependent cells are often insensitive to SHP099 when compared to EGFR-dependent cells. We find that FGFR-driven cells depend on SHP2 but exhibit resistance to SHP2 inhibitors in vitro and in vivo . Treatment of such models with SHP2 inhibitors results in an initial decrease in phosphorylated ERK1/2 (p-ERK) levels, however p-ERK levels rapidly rebound within two hours. This p-ERK rebound is blocked by FGFR inhibitors or high doses of SHP2 inhibitors. Mechanistically, compared with EGFR-driven cells, FGFR-driven cells tend to express high levels of RTK negative regulators such as the SPRY family proteins, which are rapidly downregulated upon ERK inhibition. Moreover, over-expression of SPRY4 in FGFR-driven cells prevents MAPK pathway reactivation and sensitizes them to SHP2 inhibitors. We also identified two novel combination approaches to enhance the efficacy of SHP2 inhibitors, either with a distinct site 2 allosteric SHP2 inhibitor or with a RAS-SOS1 interaction inhibitor. Our findings suggest the rapid FGFR feedback activation following initial pathway inhibition by SHP2 inhibitors may promote the open conformation of SHP2 and lead to resistance to SHP2 inhibitors. These findings may assist to refine patient selection and predict resistance mechanisms in the clinical development of SHP2 inhibitors and to suggest strategies for discovering SHP2 inhibitors that are more effective against upstream feedback activation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.27435

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 43

Metadata

Authors
Lu, H., Liu, C., Huynh, H., Le, T. B. U., LaMarche, M. J., Mohseni, M., Engelman, J. A., Hammerman, P. S., Caponigro, G., & Hao, H.-X.
Venue
Oncotarget
Published
2020-01-21
Volume
11
Issue
3
Pages
265-281
ISSN
1949-2553 (ISSN-L)
OpenAlex
W3000801543
Cited by
43
References
19
FWCI
2.07
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR. https://app.cochat.ai/papers/10.18632/oncotarget.27435
The paper
Lu, H., Liu, C., Huynh, H., Le, T. B. U., LaMarche, M. J., Mohseni, M., Engelman, J. A., Hammerman, P. S., Caponigro, G., & Hao, H.-X. (2020). Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR. Oncotarget. https://doi.org/10.18632/oncotarget.27435

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.